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ABSTRACT:
Vaccinia-related kinase 1 (VRK1) belongs to a group of sixteen kinases associated 
to a poorer prognosis in human breast carcinomas, particularly in estrogen receptor 
positive cases based on gene expression arrays. In this work we have studied the 
potential molecular mechanism by which the VRK1 protein can contribute to a poorer 
prognosis in this disease. For this aim it was first analyzed by immunohistochemistry 
the VRK1 protein level in normal breast and in one hundred and thirty six cases 
of human breast cancer. The effect of VRK1 to protect against DNA damage was 
determined by studying the effect of its knockdown on the formation of DNA repair foci 
assembled on 53BP1 in response to treatment with ionizing radiation or doxorubicin 
in two breast cancer cell lines. VRK1 protein was detected in normal breast and in 
breast carcinomas at high levels in ER and PR positive tumors. VRK1 protein level 
was significantly lower in ERBB2 positive cases. Next, to identify a mechanism that 
can link VRK1 to poorer prognosis, VRK1 was knocked-down in two breast cancer 
cell lines that were treated with ionizing radiation or doxorubicin, both inducing 
DNA damage. Loss of VRK1 resulted in reduced formation of DNA-damage repair foci 
complexes assembled on the 53BP1 scaffold protein, and this effect was independent 
of damaging agent or cell type. This observation is consistent with detection of high 
VRK1 protein levels in ER and PR positive breast cancers. We conclude that VRK1 can 
contribute to make these tumors more resistant to DNA damage-based therapies, 
such as ionizing radiation or doxorubicin, which is consistent with its association 
to a poor prognosis in ER positive breast cancer. VRK1 is potential target kinase for 
development of new specific inhibitors which can facilitate sensitization to other 
treatments in combination therapies; or alternatively be used as a new cancer drugs. 
INTRODUCTION
Breast cancer represents one of the most frequent 
tumors in humans, and despite a significant improvement 
in survival resulting from an earlier diagnosis and new 
therapies; it still represents a major medical problem. 
Several gaps need answers to improve management 
of these tumors, and identification of markers for 
radiosensitivity and chemosensitivity is one of them 
[1]. There are three major types of breast cancer based 
on the expression of estrogen and progesterone receptors 
and ERBB2, a member of the EGF receptor family. The 
combination of their expression levels identifies the major 
groups susceptible to current treatments, directed either 
to hormone receptors or the ERBB2 receptor. Also, there 
is still a smaller, but very important group that includes 
cases that are negative for these three markers, known as 
triple negative and this type of tumors still do not have a 
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suitable treatment [2].  
Gene expression analysis has led to a wealth 
of information regarding tumor characterization, and 
permitted the identification of different tumor types based 
on gene expression patterns.  In human breast cancer the 
analysis of gene expression has led to the identification 
of several kinases as potential prognostic markers [3, 4]. 
These studies identified the VRK1 kinase as a marker for 
a subgroup with a poorer prognosis within the estrogen 
receptor positive cases. This gene expression pattern is 
mostly reproduced in human breast cancer cell lines [5]. 
Moreover, the analysis of the human kinome in breast 
cancer cases led to the identification of a gene expression 
signature containing sixteen kinases that was associated 
with a poorer prognosis, and VRK1 was also present in 
this group [6]. This association was mainly detected in 
luminal tumors, suggesting their potential use as marker or 
therapeutic targets in this subgroup of breast cancers [6]. 
VRK1 is a nucleosomal, or chromatin, kinase that 
directly and stably interacts with different chromatin 
proteins such as histone H3[7], macroH2A1.2 [8], 
and HP1 [7]. In addition VRK1 also interacts and 
phosphorylates several transcription factors including 
c-Jun [9], ATF2 [10], CREB [11] and p53[12-14], all of 
them involved in oncogenesis. The VRK1 gene appeared 
late in evolution and its gene complexity parallels that of 
the p53 gene family [15], suggesting that this kinases play 
a coordinating role as organisms become more complex. 
VRK1 has been associated with control of cell cycle 
progression where it plays different roles [16]. VRK1 
is required for exit G0 cell cycle phase and entry in G1 
[17], behaving as an early gene like MYC and FOS, but 
later  is also required for chromatin condensation by 
phosphorylation of histone H3 [7, 18], nuclear envelope 
organization [19] and Golgi fragmentation late in mitosis 
[20]. In addition VRK1 has been implicated in responses 
to DNA damage induced by UV-light [14] and by ionizing 
radiation [21]. This latter effect is mediated by regulation 
of DNA repair foci assembled on the 53BP1 scaffold 
protein [22]. Reduction of VRK1 levels impaired 53BP1 
foci formation and also resulted in defective activation 
of the ATM-CHK2 pathway [21]. Moreover, in human 
cancer, VRK1 has been associated to the proliferation 
phenotype and is co-expressed with Ki67 in head and neck 
squamous cell carcinoma [23]. Also VRK1 is expressed 
at high levels, correlating with Ki67 and p63 in non-
small lung cancer [24] and high-grade astrocytomas [25]. 
These effects of VRK1 indicated that it might contribute 
to tumor prognosis by modulation of tumor proliferation 
and cellular responses to DNA-damage based treatments.
In this work we have validated that VRK1 protein is 
present at significantly higher levels in breast carcinomas 
that are positive for hormone receptors (estrogen and 
progesterone). Moreover, we provided evidence about 
VRK1 biological significance in human breast cancer 
cell lines, since this kinase contributes to cell protection 
against DNA damage induced by therapy, and this function 
can be relevant for conferring a poorer prognosis to breast 
cancer cases.
RESULTS 
Expression of VRK1 protein in normal human 
breast
Initially it was determined the presence of 
VRK1 protein in normal mammary gland tissue by 
immunohistochemistry. In human mammary gland high 
level of nuclear VRK1 protein was detected mainly in 
cells located in the luminal side (Fig. 1A). However, all 
mammary epithelial cells expressed this protein (Fig. 1A). 
Also the expression of a minor cytoplasmic subpopulation 
was detected in cytosol (Fig. 1B) using the 1F6 mAb [20, 
26]. This cytosolic subpopulation presented a similar level 
of expression in all epithelial mammary cells, independent 
of its location (Fig. 1B). Other cell types in mammary 
gland stroma presented a significantly lower level of 
cytosolic VRK1 protein.
VRK1 correlation with ER, PR and ERBB2 in 
human breast cancer
Different studies using RNA microarrays detected 
high levels of VRK1 expression in estrogen receptor 
positive breast cancer and at the same time the group with 
high VRK1 identified patients with a poorer prognosis [3, 
Figure 1: Expression of VRK1 in normal human breast 
tissue. The VRK1 protein was determined with two different 
antibodies recognizing the two VRK1 intracellular populations. 
Two magnifications are shown. A. Detection of the main nuclear 
VRK1 population with a rabbit polyclonal antibody (VC1). B. 
Detection of cytosolic subpopulation of VRK1 using the 1F6 
monoclonal antibody specific for this cytosolic subpopulation.
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4, 6, 27]. Based on this data we decided to study VRK1 
protein expression in a panel of biopsies containing 
two groups of breast cancers, ER+/ERBB2- and ER-/
ERBB2+. VRK1 positively correlated with estrogen and 
progesterone receptor positivity and inversely correlated 
with ERB2 positivity. Examples of these different levels 
of expression are shown for VRK1/ estrogen receptor (ER) 
(Fig.2) and VRK1/progesterone receptor (PR) (Fig. S1).
The relative level of VRK1 expression as a function of 
estrogen receptor positivity is shown in Fig. 2 (bottom). 
VRK1 positively correlated (P<0.0001) with either ER 
or PR, and negatively correlated with ERBB2 (P<0.002). 
Also it was detected that VRK1 is downregulated in 
ERBB2 positive tumors (Fig. S2), a situation similar to 
that reported for VRK2 and ERBB2 [28, 29].
VRK1 and VRK2 levels in human breast cancer 
cell lines
The expression of VRK1 and VRK2 as well as 
estrogen receptor and ERBB2 were determined in a panel 
of eight human breast cancer cell lines (Fig. 3A), including 
four of each type, luminal or basal [30]. Luminal type 
cell lines, which are positive for estrogen receptor, have 
in general a higher level of VRK1 than basal cell lines. 
Also in luminal cell lines the level of total VRK2 is also 
higher, in part due to expression of VRK2B isoform, but 
its significance is unknown. Also activation of MAPK 
associated in part to proliferation signaling was detected 
by the presence of phospho-Erk, whci is higher in the two 
cell lines expressing ERBB2 (HCC1569 and BT474). 
This is consistent with the negative correlation between 
ERBB2 and VRK1detected in immunohistochemistry, cell 
lines with higher level of ERBB2 showed lower VRK1 
levels. Cell lines with mutated p53 are detected by its 
accumulation and are equally distributed among luminal 
and basal cell lines as expected [30].  We selected one 
luminal, MCF7 (ER positive), and one basal, MDA-
MB-231(ER negative) cell lines to further characterize 
the consequences of manipulating their VRK1 levels. 
Figure 2: Expression of VRK1 and estrogen receptor 
in breast cancer. Different levels of VRK1 expression as a 
function of the level of estrogen receptor. VRK1 was detected 
with rabbit polyclonal VC1antibody.In the graph at the bottom 
are shown the relatives levels of VRK1 as a function of ER 
positivity or negativity. 
Figure 3: Expression of VRK1, VRK2, ER, ERBB2 
and signaling proteins in a panel of breast cancer cell 
lines. A. Expression of different proteins in eight breast cancer 
cell lines. B. Effect of VRK1 on cell growth. MDA-MB-231 
cells were transfected with siVRK1-02 (SiV1-02) or siControl 
(siCtrl) using Lipofectamine2000. After 48 hours, cells were 
treated with Doxorubicin (1 µM) and cells were counted at 0 
h, 24 h and 48 h. The mean of relative number of cells and the 
standard deviations were represented in the graph.
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Since VRK1 has been associated to proliferation it was 
determined how knockdown of VRK1 affected cell 
number using MDA-MB-231, as well as the effect of 
treatment with doxorubicin. VRK1 knockdown reduced 
increases in cell number, that was even stronger in case of 
treatment with doxorubicin (Fig. 3B), as expected based 
on the known role of VRK1 in cell proliferation.
VRK1 knockdown impaired formation of 53BP1 
foci in response to DNA damage induced by 
ionizing radiation or doxorubicin.
The level of VRK1 can regulate the ability of the 
cell to respond to DNA damage, which is a common 
mechanism to different types of therapy used in breast 
cancer. These therapies including ionizing radiation or 
doxorubicin, a topoisomerase inhibitor used in different 
combination protocols, are able to generate double-strand 
DNA breaks that will trigger protective DNA-damage 
response pathways. The level of VRK1 protein regulates 
the formation of 53BP1 DNA-repair foci induced by 
ionizing radiation in lung cancer cell lines [21]. Therefore 
it was studied if the level of VRK1 protein can affect 
the formation of 53BP1 DNA-repair foci in response to 
ionizing radiation or doxorubicin [31]. In this study two 
breast cancer cell lines were used MCF7, luminal [30], and 
MDA-MB-231, basal B [30]. Knockdown of endogenous 
VRK1 was performed with two different siVRK1 and 
the formation of 53BP1 foci, reflecting proper activation 
of DNA repair [32], was determined. The loss of VRK1 
resulted in a significant reduction of the 53BP1 foci 
induced by either ionizing radiation or doxorubicin in 
MCF7 (Fig. 4) and MDA-MB-231 (Fig. 5) cells. These 
results indicated that high VRK1 levels confer resistance 
to DNA-damage based treatments by permitting activation 
of DNA repair pathways. Facilitating DNA repair in 
DNA-damage based treatments against cancer cells can 
contribute to a poorer prognosis of tumors with high levels 
of VRK1.
DISCUSSION
  Receptor positive  breast cancer has high levels 
of VRK1, a situation that has also been reported in other 
tumors such as head and neck squamous cell carcinomas 
[23], non-small lung cancer [24] and high-grade 
astrocytomas [25]. In addition, high VRK1 levels have 
also been detected in tumors harboring p53 mutations and 
in which the VRK1-p53 downregulatory loop is defective 
[14, 33, 34].
The contribution of VRK1 to a poorer prognosis 
Figure 4: Effect of VRK1 knockdown on 53BP1 foci 
induced by ionizing radiation (IR) or doxorubicin 
in MCF7 breast cancer cells. At the left is shown the 
immunofluorescence. The number of foci 53BP1 foci counted in 
seventy-five cells is shown in the graph.  The image of the field 
is shown in Fig. S3. VRK1 was detected with rabbit polyclonal 
VC1antibody.
Figure 5: Effect of VRK1 knockdown on 53BP1 foci 
induced by ionizing radiation (IR) or doxorubicin in 
MDA-MB-231 breast cancer cells. At the left is shown the 
immunofluorescence. The number of foci 53BP1 foci counted 
in eighty-five cells is shown in the graph. The image of the field 
is shown in Fig. S4. VRK1 was detected with rabbit polyclonal 
VC1antibody.
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can be a consequence of VRK1 as a chromatin kinase  [7, 
8] since it affects cellular response to DNA damage and 
is required for the formation of 53BP1 foci in response 
to DNA double strand breaks induced by ionizing 
radiation [21]. High levels of VRK1 exert a protective 
effect against DNA damage induced either by ionizing 
radiation or chemotherapeutic drugs. ER positive tumors 
of the luminal type are characterized by an enhanced 
chemoresistance [31]. Thus, VRK1 high levels can confer 
a poorer prognosis because of their better resistance 
in tumors treated with DNA-damage based therapies. 
High VRK1 levels can also have an anti-tumoral effect 
by VRK1 specific phosphorylation of p53 in Thr18 
converting it into a transcriptionally active p53 [12, 13, 
34] that can trigger cell cycle arrest or induce death and 
subsequent elimination of tumor cells. But p53 levels are 
tightly regulated by induction of a double auto regulatory 
loop mediated by p53-dependent proteins, such as mdm2 
that targets p53 for proteasomal degradation, and DRAM 
that results in elimination of VRK1 in the autophagic 
pathway [14]. However p53 is mutated in a very large 
number of cancers, and p53 mutants are unable to induce 
downregulation of p53[33] and  VRK1[14], by different 
mechanisms. The consequence is that tumors harboring 
p53 mutations have higher levels of VRK1 by the 
inactivation of its downregulation, as has already been 
identified in lung cancer [24]. Thus, breast cancers with 
p53 mutations they will be even more resistant to DNA-
damage based treatments because they will be unable to 
induce cell death. 
Another role by which VRK1 contributes to a poorer 
tumor prognosis can be due to its role in proliferation 
[16]. VRK1 is regulated in cell cycle and its effect is 
mediated by the contribution to the coordination of 
several processes required for cell division, such as 
disassembly and reassembly of the nuclear membrane 
[19, 35], Golgi fragmentation late in mitosis [20] or 
chromatin condensation [7]. In experimental animal 
models, human breast cancer xenographs expressing high 
levels of VRK1 have a higher growth rate and invasive/
dissemination potential [36]. Thus one contribution is a 
likely consequence of its higher proliferation potential.
The role of VRK1 in controlling several aspects of 
cell proliferation [16], and its implication in p53 and DNA-
damage responses suggested that it might be a potential 
target for specific drug development  [17, 33]. Targeting 
VRK1 kinase was initially proposed based on observation 
of p53 mediated responses [13, 33], a regulatory role 
that is altered in tumors with p53 mutations [24] by a 
mechanism that requires p53-induction of the autophagic 
pathway [14]. More recently, it has been proposed that 
since VRK1 is a complementary proliferation pathway, 
its targeting might be less deleterious for cells that direct 
targeting of the main mitotic pathway [37], and thus 
opening a potentially useful therapeutic window that needs 
to be characterized. 
VRK1, like the other two members of the family, 
has a kinase domain with some structural differences 
with respect to the typical kinase-domain [38, 39]. 
These structural differences led to the proposal that 
VRK proteins are likely have a low sensitivity to most 
inhibitors, and thus specific inhibitors will have little cross 
reactivity with other kinases, thus VRK proteins have a 
low promiscuity index [40, 41]. Their low sensitivity to 
currently used kinase inhibitors supports this idea [40, 
42, 43]. Development of specific inhibitors for VRK1 is 
highly likely and they might be very useful for cancer 
treatment in two ways. In one way, VRK1 can interfere 
with cell cycle progression and division and thus prevent, 
or reduce, tumor growth and expansion [16]. On the other 
way, inhibiting VRK1 role in DNA damage response 
to ionizing radiation or chemotherapy [21] can make 
tumor cells more sensitive to these treatments, and might 
consequently permit a reduction of toxic doses in new 
protocols based on combination therapies, once VRK1 
inhibitors become available in the future. This role of 
VRK1 in DNA-damage response is in agreement with the 
predictive role of 53BP1 and BRCA1 expression in breast 
cancer [44, 45].
Breast tumors expressing estrogen receptor, but not 
ERBB2, more frequently give bone metastasis [46]. This 
is consistent with high VRK1 levels that contribute to cell 
proliferation and drug resistance, and also with high levels 
of VRK2 in these tumors [28, 29], which can facilitate cell 
invasion by regulation of Cox2 gene expression [47] and 
protection against apoptosis [48].
In conclusion high VRK1 levels can contribute to 
a poorer prognosis in breast cancer. The level of VRK1 
protein determines the sensitivity of breast cancer cells to 
DNA-damage based treatments, such as ionizing radiation 
or doxorubicin. High VRK1 protein levels confer a 
stronger resistance to treatment, which is consistent with 
a poorer prognosis. This VRK1 contribution to make cells 
more resistant to DNA-damage based therapies and by 
facilitating tumor growth and probably dissemination, an 
effect that will be further facilitated if the tumor has p53 
mutations. The underlying molecular base of this VRK1 
biological effects suggest that a similar situation is very 
likely to occur in other types of cancers and is probably 
not restricted to breast cancer.
MATERIAL AND METHODS
Breast cancer and immunohistochemistry in 
tissue arrays
Biopsies from human breast cancer were 
provided by the National Tumor Bank at CIC-Hospital 
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Universitario de Salamanca. Biopsies were prepared as 
previously reported [24]. Sections were counterstained 
with hematoxylin. VRK1 was detected with a rabbit 
polyclonal antibody [49]. For analysis of VRK1, estrogen 
and progesterone receptors and ErbB2 consecutive 
sections were used. ErbB2 or other markers were scored 
in a scale from 1 to 3, regarding both intensity of staining 
and the number of positive cells, and the final score was 
determined by multiplying the two components [28]. 
Values were compared either by the chi-square or the 
Fisher’s exact test (SPSS program version 18; SPSS, 
Chicago), and differences with a P < 0.05 were considered 
statistically significant [23, 24]. Clinical data was not 
available for analysis in this series.
Antibodies
In immunohistochemistry, nuclear VRK1 was 
detected with rabbit polyclonal antibody VC1 [26] or 
HPA000660 from Sigma; the cytosolic subpopulation 
was detected with murine monoclonal antibody 1F6 [26]. 
Human VRK1 was detected in immunofluorescences and 
western blots with monoclonal 1B5 [26] or polyclonal 
anti-VRK1 from Sigma (HPA000660). Antibodies 
1B5 and anti-VRK1 (Sigma) were used in western 
blots at dilution 1:1000 and in immunofluorescences 
at 1:50 or 1:100 respectively. 53BP1 was detected in 
immunofluorescences with either polyclonal 53BP1 (H-
300) (Santa Cruz Biotechnology) or monoclonal anti-
53BP1 from Upstate at 1:50 dilution (no differences 
in foci number or size were found between the two 
antibodies detecting 53BP1). Anti-ER (SP1, rabbit 
polyclonal antibody from Master Diagnostic, Granada, 
Spain). Anti-HER2/ErbB2 (44E7 from Cell Signaling); 
anti-pErk (E-4); anti-Erk2 (C-14); anti-p53 (Pab 1801 and 
DO-1) all from Santa Cruz Biotechnology (Santa Cruz, 
CA). β-actin was detected with monoclonal antibody 
AC15 (Sigma, St. Louis, MO). The secondary antibodies 
used for immunoblots: anti-(mouse-HRP) and anti-(rabbit-
HRP) were from GE Healthcare. Bands were visualized 
with an ECL kit (GE Healthcare) followed by exposure to 
X-Ray films (Fujifilm). The secondary antibodies used for 
immunofluorescences were FluoroLinkCy2 anti-mouse, 
FluoroLinkCy2 anti-rabbit, FluoroLinkCy3 anti-mouse 
and FluoroLinkCy3 anti-rabbit from GE Healthcare.
Cell lines, transfections and immunoblots
Breast cancer cell lines, MCF7 and MDA-MB-231, 
were obtained from the ATCC, and their characterization 
in the context of breast cancer phenotypes has been 
published [5, 30]. MDA-MB-231 and MCF7 breast 
cancer cells, [50] were grown in DMEM with 10% fetal 
bovine serum. The methods for cell lysates and conditions 
for western blot have been reported [49, 51, 52]. Several 
additional cell lines were used including luminal and basal 
types. Luminal breast cancer cell lines: BT474, T47D and 
ZR75B were grown in RPMI.  Basal Breast cancer cell 
lines: BT549 (basal B) and HCC1569 (basal A) were 
grown in RPMI; HS587T (basal B), MDA-MB-231 (basal 
B) were grown in DMEM. Their molecular characteristics 
have been reported [30].
DNA damage
DNA damage was induced by cell irradiation with 3 
Gy using a Gammacell 1000 Elite irradiator (Theratronics, 
Ottawa, Canada) with a 137Cs source.  Cells were treated 
with doxorubicin (Sigma, St. Louis, MO) for the time and 
dose indicated in individual experiments.
VRK1 knockdown
Specific silencing of VRK1 was performed 
using siVRK1-02 (siV1-02), designed with the 
SMARTselection algorithm (Dharmacon, Lafayette, 
CO) and obtained from Dharmacon (DHARMACON 
RNA Technologies). The sequence target of siVRK1-02 
is 5’-CAAGGAACCTGGTGTTGAA-3’.  As negative 
control, the “ON-TARGETplus siCONTROL Non-
targeting siRNA” from DHARMACON was used. The 
efficiency of RNAi transfection was determined with 
“siGLO RISC-free siRNA” (DHARMACON) labeled 
with a red fluorochrome [21]. 
Cells were transfected with the indicated siRNA 
at a concentration of 20 nM using Lipofectamine 2000 
Reagent” (Invitrogen, Carlsbad, CA) according to 
manufactures instructions. After transfection, cells were 
processed for specific experiments as previously reported 
[14, 17, 24]. 
Immunofluorescence and confocal microscopy
MCF7 and MDA-MB-231 cells were grown on 
uncoated glass coverslips, placed in 60-mm plates. Cells 
were prepared as previously reported [49]. Fluorescence 
images were captured with a LEICA TCS SP5 DMI-
6000B confocal microscope (Leica), using the following 
lasers: Argon (488 nm), DPSS (561 nm) and UV Diode 
(405 nm).  Fluorescence images were analyzed with 
LEICA LAS AF (Leica) and ImageJ (NIH, http://rsb.info.
nih.gov/ij) software.
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